Clinical trials: Arsenic Trioxide
Leukemia, Lymphocytic, Chronic, B-Cell
Combination of Ibrutinib and As2O3 in the Treatment of CLL
The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia
- Trial name
- NCT02757040
- Testing
- Ibrutinib combined with As2O3, ibrutinib
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital